(Q35011129)

English

Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Philip W. Kantoff

16

object named as

Philip W Kantoff

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Mary-Ellen Taplin

1

object named as

Mary-Ellen Taplin

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

7

object named as

Tomasz M Beer

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

author name string

Meredith M Regan

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Yoo-Joung Ko

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Glenn J Bubley

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Stephen E Duggan

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Lillian Werner

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Christopher W Ryan

8

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Paul Mathew

9

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Shi-Ming Tu

10

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Samuel R Denmeade

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

William K Oh

12

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Oliver Sartor

13

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Christos S Mantzoros

14

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Roger Rittmaster

15

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Steven P Balk

17

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

language of work or name

0 references

publication date

3 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

7099-7105

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

Targeting CYP17: established and novel approaches in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

The androgen axis in recurrent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

Ras signaling in prostate cancer progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

The influence of finasteride on the development of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

Bilateral adrenalectomy for palliative treatment of prostatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

8 July 2018

Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

25 October 2018

Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

25 October 2018

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

25 October 2018

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

25 October 2018

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

25 October 2018

A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3644858

25 October 2018

Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19887483

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19887483

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19887483

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19887483

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-09-1722

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35011129&oldid=2186343081"